NeuroSense Therapeutics L... (NRSNW)
NeuroSense Therapeutics Ltd. Statistics
Share Statistics
NeuroSense Therapeutics Ltd. has 20.71M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 20.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 0.62% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 70 |
| FTD / Avg. Volume | 0.7% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -1.06 and the forward PE ratio is null. NeuroSense Therapeutics Ltd.'s PEG ratio is 0.07.
| PE Ratio | -1.06 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -5.71 |
| P/FCF Ratio | -1.26 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeuroSense Therapeutics Ltd..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of -0.08.
| Current Ratio | 0.84 |
| Quick Ratio | 0.84 |
| Debt / Equity | -0.08 |
| Total Debt / Capitalization | -8.2 |
| Cash Flow / Debt | -59.52 |
| Interest Coverage | -21.91 |
Financial Efficiency
Return on equity (ROE) is 5.39% and return on capital (ROIC) is 695.67%.
| Return on Equity (ROE) | 5.39% |
| Return on Assets (ROA) | -3.18% |
| Return on Capital (ROIC) | 695.67% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-561,500 |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -32.27% in the last 52 weeks. The beta is 1.25, so NeuroSense Therapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | -32.27% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 45.7 |
| Average Volume (20 Days) | 10.03K |
Income Statement
| Revenue | n/a |
| Gross Profit | -97K |
| Operating Income | -12.05M |
| Net Income | -10.11M |
| EBITDA | -10.63M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.83 |
Balance Sheet
The company has 2.64M in cash and 142K in debt, giving a net cash position of 2.5M.
| Cash & Cash Equivalents | 2.64M |
| Total Debt | 142K |
| Net Cash | 2.5M |
| Retained Earnings | -32.07M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -8.45M and capital expenditures -29K, giving a free cash flow of -8.48M.
| Operating Cash Flow | -8.45M |
| Capital Expenditures | -29K |
| Free Cash Flow | -8.48M |
| FCF Per Share | -0.62 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRSNW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -488.24% |
| FCF Yield | -240.9% |
Analyst Forecast
Currently there are no analyst rating for NRSNW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |